Shares of Transgenomic Inc (NASDAQ: TBIO), engaged in advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its molecular technologies, clinical and research services, recorded over 12.0% gain during each of the past two consecutive trading sessions with significant number of shares exchanging hands. TBIO was among the top performers in the U.S. healthcare sector after gaining 12.8% and closed at $3.51 Wednesday, while recording significant trading volumes of 203,965 shares. It has also broken its key technical resistance level of 200-Day DMA at $3.35. TBIO recently announced that the commercial launch of its Multiplexed ICE COLD-PCR (MX-ICP) product line is scheduled in the first quarter of 2015. During the past 5-trading sessions, TBIO gained 65.6% with daily average trading volumes of 180,448 shares, while the stock accumulated 56.0% gain during the past one month with daily average trading volumes of 77,592 shares. The stock is up 74.6% year-to-date.
Company Description:
Transgenomic, Inc. (NASDAQ: TBIO) provides research tools to the life sciences industry. These tools enable researchers to discover and understand variation in the human genetic code, or genome, in order to accelerate and improve drug development and diagnostics.
1-Year Stock Chart:
Source: Bloomberg
